Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
American ginseng (Panax quinquefolius) contains ginsenosides that modulate glucose metabolism and cellular energy production. Clinical studies demonstrate its effectiveness in improving glycemic control in type 2 diabetes and potentially reducing cancer-related fatigue.
Origin & History
American Ginseng (Panax quinquefolius) is a perennial herb native to the deciduous forests of eastern North America, harvested from the roots of plants in the Araliaceae family. The active components are extracted from dried roots using water or ethanol extraction methods to produce standardized extracts rich in ginsenosides, which are triterpene saponins.
Research Narrative (Provisional)
A WHO review identified 22 clinical trials of American ginseng (16.4% of 134 total ginseng trials), with 94% randomized and 78.4% double-blind placebo-controlled designs. Key studies include a diabetes RCT (NCT02923453) showing glycemic benefits at 3g/day and a large cancer fatigue trial (n=290, PMID: 19415341) testing 750-2000mg/day doses, though a systematic review (PMID: 32691627) noted limited evidence for cancer-related fatigue.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
American Ginseng root is a low-calorie botanical ingredient (~350 kcal/100g dry weight) with a composition dominated by bioactive carbohydrates and specialized secondary metabolites. Primary macronutrients: carbohydrates (~70-80% dry weight, predominantly polysaccharides and starch), protein (~10-12% dry weight, including arginine-rich peptides), fat (~1-2% dry weight). Key bioactive compounds: Ginsenosides (total ~2-10% dry weight in quality root; dominant fractions Rb1 ~0.5-2%, Rb2, Rc, Rd, Re ~0.1-0.5% each, Rg1 typically lower in quinquefolius vs. Asian ginseng) — American Ginseng is notably enriched in Rb1 relative to Rg1, distinguishing its pharmacological profile. Polysaccharides (quinquefolans A, B, C) at ~5-12% dry weight contribute to immunomodulatory and hypoglycemic effects. Polyacetylenes (panaxynol, panaxydol) present at trace levels (~0.01-0.05%). Phenolic acids including ferulic acid, p-coumaric acid, and vanillic acid at ~0.1-0.3% collectively. Essential oils (~0.05-0.3%) containing β-elemene and other sesquiterpenes. Micronutrients: potassium (~1,200-1,800 mg/100g dry), calcium (~300-500 mg/100g dry), magnesium (~100-200 mg/100g dry), zinc (~2-4 mg/100g dry), manganese (~3-6 mg/100g dry), iron (~10-20 mg/100g dry). B vitamins present at low levels including niacin (~1-2 mg/100g dry) and thiamine (~0.1 mg/100g dry). Dietary fiber: ~15-20% dry weight (mix of soluble and insoluble). Bioavailability notes: Ginsenoside oral bioavailability is inherently low (~1-5% for intact saponins); gut microbiota extensively metabolize Rb1 and other protopanaxadiols to compound K (20-O-β-glucopyranosyl-20(S)-protopanaxadiol), which is considered a primary active absorptive metabolite with significantly higher intestinal permeability. Standardized extracts (typically standardized to ≥5% total ginsenosides) show more predictable pharmacokinetic profiles than raw root powder. The 3g/day dose used in NCT02923453 trials provides approximately 150mg total ginsenosides at 5% standardization.
Reported Mechanism (Provisional)
American ginseng's primary bioactive compounds, ginsenosides (particularly Rb1 and Rg1), enhance insulin sensitivity by activating AMPK pathways and improving glucose uptake in skeletal muscle. The ginsenosides also modulate the hypothalamic-pituitary-adrenal axis, reducing cortisol levels and supporting cellular energy metabolism through mitochondrial function enhancement.
Clinical Narrative (Provisional)
A double-blind randomized controlled trial (NCT02923453) demonstrated that 3g daily of American ginseng significantly reduced HbA1c levels and improved blood pressure and lipid profiles in type 2 diabetes patients. A pilot RCT with 290 cancer patients showed non-significant trends favoring 1000-2000mg daily for fatigue reduction, though larger studies are needed. Most clinical evidence focuses on glycemic control, with consistent positive results across multiple small to medium-sized trials. The evidence quality is moderate, with most studies lasting 8-12 weeks.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.